U.S. markets close in 48 minutes

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
35.74+0.17 (+0.48%)
As of 03:10PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Head and Shoulders Top

Head and Shoulders Top

Previous Close35.57
Bid35.79 x 900
Ask35.92 x 800
Day's Range35.13 - 36.04
52 Week Range30.12 - 58.35
Avg. Volume213,471
Market Cap2.09B
Beta (5Y Monthly)0.74
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for XNCR

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Xencor, Inc.
    XNCR: What does Argus have to say about XNCR?XENCOR INC has an Investment Rating of HOLD; a target price of $39.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Benzinga

    Xencor Outlicenses Autoimmune Disease Candidate To Zenas BioPharma

    Zenas BioPharma has acquired from Xencor Inc (NASDAQ: XNCR) exclusive worldwide rights to develop, manufacture, and commercialize obexelimab. Obexelimab is a potential first-in-class bifunctional antibody that targets CD19 with its variable domain. It uses Xencor's XmAb Immune Inhibitor Fc Domain to target FcγRIIb, a receptor that inhibits the function of B-cells, which are essential components in the immune system. Under the terms of the new agreement, Zenas will issue a warrant giving Xencor t

  • Simply Wall St.

    What Is The Ownership Structure Like For Xencor, Inc. (NASDAQ:XNCR)?

    A look at the shareholders of Xencor, Inc. ( NASDAQ:XNCR ) can tell us which group is most powerful. Generally...

  • Benzinga

    Novartis Dumps Another Bispecific Candidate From Xencor Deal

    Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The move will take effect next February, Xencor Inc (NASDAQ: XNCR) said. Xencor will drop the development of the drug altogether as well, saying it has no plans for in-house research. Novartis will cover its share of the costs until August 2022. Novartis and Xencor originally agreed to develop vibecotamab, previously known as XmAb14045, back in 2